A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man.

R M Evans; G C Doelle; J Lindner; V Bradley; D Rabin

doi:10.1172/JCI111200

Find articles by Evans, R. in: PubMed | Google Scholar

Find articles by Doelle, G. in: PubMed | Google Scholar

Find articles by Lindner, J. in: PubMed | Google Scholar

Find articles by Bradley, V. in: PubMed | Google Scholar

Find articles by Rabin, D. in: PubMed | Google Scholar

Published in Volume 73, Issue 1 on January 1, 1984
J Clin Invest. 1984;73(1):262–266. https://doi.org/10.1172/JCI111200.
© 1984 The American Society for Clinical Investigation

Published January 1, 1984 - Version history

The effect of the luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6,Pro9-NEth]LHRH (LHRHA), on luteinizing hormone (LH) bioactivity was assessed with a rat interstitial cell assay in four men during a 14-d treatment period. Biologic/immunologic (B/I) ratios were unchanged initially with treatment but by day 12 had fallen to levels lower than basal values. Frequent sampling on day 12 revealed blunted gonadotropin responsiveness to LHRHA and absence of spontaneous LH pulsations. Despite continued administration of LHRHA, human chorionic gonadotropin administration resulted in elevated B/I ratios and testosterone levels. Further characterization of the serum immunoreactive LH by Sephadex chromatography revealed a later elution profile during treatment with LHRHA. Thus, LHRHA appears to act, in part, by modification of the bioactivity of LH in man.

Click on an image below to see the page. View PDF of the complete article